K Number
K021837
Date Cleared
2002-08-30

(87 days)

Product Code
Regulation Number
874.3302
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The use of BAHA hearing aid for SSD is intended to improve speech recognition.

The single sided deafness (SSD) indication for BAHA hearing aid is intended for patients who suffer from unilateral sensorineural deafness on one ear while the other ear has normal hearing. Normal hearing is defined as PTA AC threshold equal to or better than 20dB measured at 0.5, 1, 2 and 3 kHz.

BAHA for SSD is also indicated for patients who are indicated for an AC CROS but who for some reason cannot or will not use an AC CROS.

Device Description

The BAHA is a bone conduction-type hearing aid. Unlike conventional hearing aids, which depend on acoustic coupling through the air, the BAHA is based on a bone conduction technology.

The BAHA hearing aid is connected to a fixture pillar, which has been surgically placed in the bone behind the deaf ear. Sound is transmitted through the bones of the skull to the hearing ear with the normal functioning cochlea.

AI/ML Overview

Here's a breakdown of the acceptance criteria and study information for the Branemark Bone Anchored Hearing Aid (BAHA) for Single Sided Deafness (SSD), based on the provided text:

Acceptance Criteria and Reported Device Performance

The provided text focuses on the substantial equivalence determination for the BAHA for SSD. While it doesn't explicitly list "acceptance criteria" in a table format with numerical targets, the underlying assumption for substantial equivalence is that the device performs at least as well as or similarly to the predicate devices for its intended use.

The primary performance metrics assessed relate to improvement in hearing and speech recognition.

Acceptance Criteria (Implied by Substantial Equivalence and Intended Use)Reported Device Performance (from Clinical Study)
Improvement of hearing for patients with SSDA clinical study was conducted to establish the benefits of BAHA for SSD.
Improvement of speech recognition for SSD patientsClinical study included audiometric evaluation of speech perception in noise.
Subjective improvement in daily listening situations for SSD patientsClinical study included a subjective questionnaire (APHAB).

Study Details

  1. Sample Size used for the test set and the data provenance:

    • Sample Size: Not specified in the provided text.
    • Data Provenance: Not specified (e.g., country of origin, retrospective/prospective). The text only states "A clinical study was conducted."
  2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

    • This information is not provided in the document. The study evaluated audiometric performance and subjective responses directly from patients, not through expert review of data that would require a ground truth panel.
  3. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

    • Not applicable/Not specified. The study primarily relies on direct audiometric measurements and patient-reported outcomes (questionnaires), which do not typically involve adjudication in the same way as image interpretation studies.
  4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

    • No MRMC comparative effectiveness study was done, as this device is a hearing aid, not an AI-assisted diagnostic tool for human readers.
  5. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

    • Not applicable. The BAHA is a medical device that physically aids hearing; it is not an algorithm, and its performance is inherently human-in-the-loop (the patient wearing it).
  6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

    • The "ground truth" for the effectiveness of the BAHA in this context would be:
      • Audiometric evaluation of speech perception in noise: Objective measures of how well patients could understand speech in challenging listening environments.
      • Subjective questionnaire (APHAB): Patient-reported outcomes on the benefit and satisfaction with the device in real-world situations.
  7. The sample size for the training set:

    • Not applicable. This is a medical device, not an AI/machine learning model that requires a "training set."
  8. How the ground truth for the training set was established:

    • Not applicable. See point 7.

{0}------------------------------------------------

K021837

SECTION 2. SUMMARY AND CERTIFICATION

A. 510(K) SUMMARY

Summary of Safety and Effectiveness

SUBMITTER'S NAME:Entific Medical Systems
ADDRESS:P:O: Box 16024SE-412 21 GöteborgSweden
CONTACT PERSON:Constance Bundy
TELEPHONE NUMBER:763-574-1976
FAX NUMBER:763-574-2437
DATE OF SUBMISSION:June 1. 2002

1. Identification of device

Proprietary Name: Branemark Bone Anchored Hearing Aid Common Name: BAHA™M Classification Status: Class II per regulations 21 CFR § 874.3300 Product Codes: LXB

2. Equivalent devices

Entific Medical Systems believes that the single sided deafness (SSD) indication for BAHA hearing aid is substantially equivalent regarding intended use to air conduction hearing aids with a CROS unit (exempt from 510(k)). The BAHA device and its fitting procedure is identical to the Branemark BAHA cleared in 510(k) 955713.

3. Description of the Device

The BAHA is a bone conduction-type hearing aid. Unlike conventional hearing aids, which depend on acoustic coupling through the air, the BAHA is based on a bone conduction technology.

The BAHA hearing aid is connected to a fixture pillar, which has been surgically placed in the bone behind the deaf ear. Sound is transmitted through the bones of the skull to the hearing ear with the normal functioning cochlea.

4. Intended use

BAHA hearing aid for SSD is intended for patients who suffer from unilateral sensorineural deafness.

BAHA hearing aid transmits the sound from the deaf side through the bones in the skull to the normal functioning cochlea and is intended to improve speech recognition.

{1}------------------------------------------------

Technological characteristics, comparison to predicate device. ડ.

Comparison table

CharacteristicBAHA for singlesided deafness(SSD)Air conductionHearing Aids withCROS unitBAHA - BranemarkBone AnchoredHearing aidS/Eq
MaterialSame as BAHAMultipleImplant: TitaniumAbutment Snap:PEEKYes
Intended useImprovement ofhearing and speechrecognition for SSDpatientsImprovement ofhearing and speechrecognition for SSDpatientsImprovement ofhearing for patientswith conductive andmixed hearing lossesYes
PowerrequirementSame as BAHAN/AZinc-airYes
Max gainSame as BAHAN/A33dBYes
FrequencyresponseSame as BAHAN/A125 Hz - 8KHzYes
ManufacturerEntific MedicalSystemsN/AEntific MedicalSystems
ClassificationcodeLXBESDLXB
K-numberPendingExemptK955713

CROS = Contra-lateral Routing Of Signals

6. Discussion of testing

A clinical study was conducted to establish the benefits of BAHA for SSD including audiometric evaluation of speech perception in noise as well as a subjective questionnaire (APHAB).

7. Conclusion

It is the conclusion of Entific Medical Systems that the BAHA for SSD is substantially equivalent to devices already on the market, both cleared by and exempt from the 510(k) process and presents no new concerns about safety and effectiveness.

{2}------------------------------------------------

B. TRUTH AND ACCURACY CERTIFICATION, BAHA FOR SINGLE SIDED DEAFNESS

I certify that, in my capacity as Quality and Regulatory Manager, I believe, to the best of my knowledge, that all data and information submitted in this premarket notification are truthful and accurate, and that no material fact has been omitted.

8

Fan Callentrat

Quality and Regulatory Manager, Entific Medical Systems

May 24, 2002 Date

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing to the right, with flowing lines beneath them. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" is arranged in a circular fashion around the image.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 3 0 2002

Entific Medical Systems c/o Constance Bundy Regulatory Consultant to Entific Medical Systems C.G. Bundy Associates, Inc. 6740 Riverview Terrace Minneapolis, MN 55432

Re: K021837

Trade/Device Name: BRANEMARK Bone-Anchored-Hearing Aid (BAHA™) for Single Sided Deafness (SSD)

Regulation Number: 874.3300 Regulation Name: Hearing Aid Regulatory Class: Class II Product Code: LXB Dated: June 1, 2002 Received: June 4, 2002

Dear Ms. Bundy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may. therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

Page 2 - Constance Bundy

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address . http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

A. Ralph Rosenthal

A. Ralph Rosenthal, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

{5}------------------------------------------------

B. INDICATIONS FOR USE

510(k) Number K021837

Device Name: The BRÅNEMARK Bone-Anchored-Hearing Aid (BAHATM).

Indications for Use:

The use of BAHA hearing aid for SSD is intended to improve speech recognition.

The single sided deafness (SSD) indication for BAHA hearing aid is intended for patients who suffer from unilateral sensorineural deafness on one ear while the other ear has normal hearing. Normal hearing is defined as PTA AC threshold equal to or better than 20dB measured at 0.5, 1, 2 and 3 kHz.

BAHA for SSD is also indicated for patients who are indicated for an AC CROS but who for some reason cannot or will not use an AC CROS.

Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Ophthalmic Ear, Nose and Throat Devises
510(k) NumberK021837
Prescription Use (Per 21 CFR 801.109)
OR
Over the Counter Use
Prescription Use (Per 21 CFR 801.109)

(Please do not write below this line - continue on another page if needed)

§ 874.3302 Bone-conduction hearing aid.

(a)
Identification. A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.(b)
Classification. Class II.